

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2022/204581 A9

(43) International Publication Date
29 September 2022 (29.09.2022)

WIPO | PCT

(51) International Patent Classification:

G01N 33/574 (2006.01) A61K 39/395 (2006.01)
A61K 39/39 (2006.01) G01N 33/569 (2006.01)

(21) International Application Number:

PCT/US2022/022063

(22) International Filing Date:

25 March 2022 (25.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/166,824	26 March 2021 (26.03.2021)	US
63/202,260	03 June 2021 (03.06.2021)	US
63/302,999	25 January 2022 (25.01.2022)	US
63/313,386	24 February 2022 (24.02.2022)	US

(71) Applicant: **SCHOLAR ROCK, INC.** [US/US]; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).


(72) Inventors: **LEE-HOEFLICH, Si Tuen**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **BRUECKNER, Christopher**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **MARTIN, Constance**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **FAUCETTE, Ryan**; 301 Binney Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: **JACOBSTEIN, Jeffrey M.**; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

(54) Title: TGF-BETA INHIBITORS AND USE THEREOF

FIG. 1



(57) Abstract: The present disclosure provides TGFβ inhibitor therapy for treating immunosuppressive conditions, such as cancer. Methods of predicting and monitoring therapeutic response are disclosed. Related compositions, methods and therapeutic use are also disclosed.

[Continued on next page]

RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

01 December 2022 (01.12.2022)

(48) Date of publication of this corrected version:

12 January 2023 (12.01.2023)

(15) Information about Correction:

see Notice of 12 January 2023 (12.01.2023)